Genmab pipeline hype makes investment bank uneasy

The expectations for Genmab's pipeline are too high, says Germany-based investment bank Berenberg Bank, which has changed its share recommendation as it cannot justify the current pricing.

Photo: Lars Møller / Genmab / PR

Although Genmab has been called a "superstar" and "one of the best European biotech companies," Berenberg Bank has changed its recommendation to "sell", with a target price of DKK 2,200 (USD 334).

In a notice, the bank recognizes that sales of Genmab's cancer drug Darzalex are expected to reach top sales of USD 12bn.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs